Ibrahim Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ibrahim Ibrahim has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Matthew C. Wright
Translational and Clinical Research Institute, Level 4 Leech, Newcastle University, Newcastle Upon Tyne, NE2 4HH, United Kingdom
2 shared publications Ahmed Abdelmoneim Khoreba
Department of Internal medicine, Faculty of Medicine, Al-Azhar University, Egypt
1 shared publication- Alex Charlton
School of Natural and Environmental Sciences, Bedson Building, Newcastle University, NE1 8QB, United Kingdom
1 shared publication Alistair C. Leitch
Institute of Translation and Clinical Research, Newcastle University, Newcastle Upon Tyne, NE2 4AA, United Kingdom
1 shared publication- Alistair C. Leitch
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4AA, UK
1 shared publication Anisah Khairunnisa
Department of Ophthalmology, Faculty of Medicine, Sriwijaya University Mohammad Hoesin Palembang, South Sumatera
1 shared publication
Latest Publications
- Open Access
- 11 November 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7, 100978
PB1151 Performance Evaluation of a Reflexive Algorithm for Suspected Heparin Induced Thrombocytopenia (HIT)
- 11 November 2023
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 7, 100978
Open AccessPB1151 Performance Evaluation of a Reflexive Algorithm for Suspected Heparin Induced Thrombocytopenia (HIT)
- Open Access
- 20 August 2022
- Published by Egyptian Knowledge Bank in Al-Azhar International Medical Journal
Assessment of serum c-peptide level as a risk factor for atherosclerosis and myocardial dysfunction in Egyptian patients with type 2 DM
Background: Until recent studies showed that C-peptide can activate intracellular signalling pathways in a variety of cell types, C-peptide was thought to be physiologically inert1. The connection between C-peptide concentrations and microvascular and macrovascular issues in type 2 diabetes can be a good indication of DM complications.. Objective: To assess serum C-peptide level as a risk factor for atherosclerosis and myocardial dysfunction in Egyptian patients with type 2 diabetes mellitus. Patients and methods: A cross-sectional comparative clinically controlled study involved 60 patients with type 2 diabetes mellitus (the patient group) and another 30 normal healthy individuals (the control group) and both groups are matched in age and sex, both groups were subjected to a thorough clinical examination, carotid Doppler intimal thickness [CIMT], echocardiography, Abdominal Ultrasonography (US), blood glucose levels, HOMA IR, liver, kidney functions, complete lipid profile and C-Peptide levels. A Comparison of the difference in C-peptide level between patients with type 2 diabetes and normal controls in the Egyptian population and its correlation with markers of atherosclerosis and myocardial dysfunction was performed. Results: There is elevation of serum C-peptide levels in type 2 DM group than control (mean 1.82 ±0.55 vs. 1.21 ±0.24, respectively), Which was statistically significant (P <0.05). Correlation coefficient of C-peptide levels with various cardiovascular risk factors was statistically significant positive in the diabetic group (p <0.05). Conclusion: C-peptide has been demonstrated to be associated with microvascular complications such as atherosclerosis and can be used as a useful tool for diagnosis of subclinical myocardial injury.
- 20 August 2022
- Published by Egyptian Knowledge Bank in Al-Azhar International Medical Journal
Open AccessAssessment of serum c-peptide level as a risk factor for atherosclerosis and myocardial dysfunction in Egyptian patients with type 2 DM
Background: Until recent studies showed that C-peptide can activate intracellular signalling pathways in a variety of cell types, C-peptide was thought to be physiologically inert1. The connection between C-peptide concentrations and microvascular and macrovascular issues in type 2 diabetes can be a good indication of DM complications.. Objective: To assess serum C-peptide level as a risk factor for atherosclerosis and myocardial dysfunction in Egyptian patients with type 2 diabetes mellitus. Patients and methods: A cross-sectional comparative clinically controlled study involved 60 patients with type 2 diabetes mellitus (the patient group) and another 30 normal healthy individuals (the control group) and both groups are matched in age and sex, both groups were subjected to a thorough clinical examination, carotid Doppler intimal thickness [CIMT], echocardiography, Abdominal Ultrasonography (US), blood glucose levels, HOMA IR, liver, kidney functions, complete lipid profile and C-Peptide levels. A Comparison of the difference in C-peptide level between patients with type 2 diabetes and normal controls in the Egyptian population and its correlation with markers of atherosclerosis and myocardial dysfunction was performed. Results: There is elevation of serum C-peptide levels in type 2 DM group than control (mean 1.82 ±0.55 vs. 1.21 ±0.24, respectively), Which was statistically significant (P <0.05). Correlation coefficient of C-peptide levels with various cardiovascular risk factors was statistically significant positive in the diabetic group (p <0.05). Conclusion: C-peptide has been demonstrated to be associated with microvascular complications such as atherosclerosis and can be used as a useful tool for diagnosis of subclinical myocardial injury.
- Open Access
- 1 July 2021
- Published by Elsevier in Toxicology
- Vol. 459, 152854
The methylimidazolium ionic liquid M8OI is detectable in human sera and is subject to biliary excretion in perfused human liver
- 1 July 2021
- Published by Elsevier in Toxicology
- Vol. 459, 152854
Open AccessThe methylimidazolium ionic liquid M8OI is detectable in human sera and is subject to biliary excretion in perfused human liver
- Open Access
- 26 June 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (6) , e0218135
Expression of serine/threonine protein kinase SGK1F promotes an hepatoblast state in stem cells directed to differentiate into hepatocytes
The rat pancreatic AR42J-B13 (B-13) cell line differentiates into non-replicative hepatocyte-like (B-13/H) cells in response to glucocorticoid. Since this response is dependent on an induction of serine/threonine protein kinase 1 (SGK1), this may suggest that a general pivotal role for SGK1 in hepatocyte maturation. To test this hypothesis, the effects of expressing adenoviral-encoded flag tagged human SGK1F (AdV-SGK1F) was examined at 3 stages of human induced pluripotent stem cell (iPSC) differentiation to hepatocytes. B-13 cells infected with AdV-SGK1F in the absence of glucocorticoid resulted in expression of flag tagged SGK1F protein; increases in β-catenin phosphorylation; decreases in Tcf/Lef transcriptional activity; expression of hepatocyte marker genes and conversion of B-13 cells to a cell phenotype near-similar to B-13/H cells. Given this demonstration of functionality, iPSCs directed to differentiate towards hepatocyte-like cells using a standard protocol of chemical inhibitors and mixtures of growth factors were additionally infected with AdV-SGK1F, either at an early time point during differentiation to endoderm; during endoderm differentiation to anterior definitive endoderm and hepatoblasts and once converted to hepatocyte-like cells. SGK1F expression had no effect on differentiation to endoderm, likely due to low levels of expression. However, expression of SGK1F in both iPSCs-derived endoderm and hepatocyte-like cells both resulted in promotion of cells to an hepatoblast phenotype. These data demonstrate that SGK1 expression promotes an hepatoblast phenotype rather than maturation of human iPSC towards a mature hepatocyte phenotype and suggest a transient role for Sgk1 in promoting an hepatoblast state in B-13 trans-differentiation to B-13/H cells.
- 26 June 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (6) , e0218135
Open AccessExpression of serine/threonine protein kinase SGK1F promotes an hepatoblast state in stem cells directed to differentiate into hepatocytes
The rat pancreatic AR42J-B13 (B-13) cell line differentiates into non-replicative hepatocyte-like (B-13/H) cells in response to glucocorticoid. Since this response is dependent on an induction of serine/threonine protein kinase 1 (SGK1), this may suggest that a general pivotal role for SGK1 in hepatocyte maturation. To test this hypothesis, the effects of expressing adenoviral-encoded flag tagged human SGK1F (AdV-SGK1F) was examined at 3 stages of human induced pluripotent stem cell (iPSC) differentiation to hepatocytes. B-13 cells infected with AdV-SGK1F in the absence of glucocorticoid resulted in expression of flag tagged SGK1F protein; increases in β-catenin phosphorylation; decreases in Tcf/Lef transcriptional activity; expression of hepatocyte marker genes and conversion of B-13 cells to a cell phenotype near-similar to B-13/H cells. Given this demonstration of functionality, iPSCs directed to differentiate towards hepatocyte-like cells using a standard protocol of chemical inhibitors and mixtures of growth factors were additionally infected with AdV-SGK1F, either at an early time point during differentiation to endoderm; during endoderm differentiation to anterior definitive endoderm and hepatoblasts and once converted to hepatocyte-like cells. SGK1F expression had no effect on differentiation to endoderm, likely due to low levels of expression. However, expression of SGK1F in both iPSCs-derived endoderm and hepatocyte-like cells both resulted in promotion of cells to an hepatoblast phenotype. These data demonstrate that SGK1 expression promotes an hepatoblast phenotype rather than maturation of human iPSC towards a mature hepatocyte phenotype and suggest a transient role for Sgk1 in promoting an hepatoblast state in B-13 trans-differentiation to B-13/H cells.
- Open Access
- 31 January 2016
- Published by Pesatuan Dokter Spesialis Mata Indonesia in Ophthalmologica Indonesiana
- Vol. 41 (2)
Identification of A1286C Methylenetetrahydrofolate Reductase Gene Polymorphism in Orbital Region Basal Cell Carcinoma Patients
Background: The development of basal cell carcinoma (BCC) shows variations among individuals. The risk factor for development of BCC related to environtmental factor especially exposure to ultraviolet radiation and individual factor. The one of internal risk factor contribute to basal cell carcinoma developmental is genetic instability include defects in folic acid synthesis or DNA synthesis. The critical enzim that participate in the process is regulated by Methylenetetrahydrofolate Reductase (MTHFR) gene. Method: This study was descriptive observational with case study involved 10 orbital region basal cell carcinoma. The diagnosis was based on histopathologic examination of the tumor. Genotype frequencies of A1286C polymorphism were studied by Polymerase Chain Reaction (PCR), amplification and restriction fragment length polymorphism analyses using MboII enzyme. Result: In the present study, from 10 subjects we found male was 7 people (70%) and female was 3 people (30%). Majority of subjects have history of having a job in the sunlight. The most commont of the BCC is nodular (80%). There is one subject with recurrent case. Analysis result of A1286C MTHFR gene show wild type in all cases. Conclusion: There’s no A1286C substitution methylenetetrahydrofolate reductase gene were identified. The whole subjects are wild type.Keywords: basal cell carcinoma, orbital region, folic acid, polymorphism, A1286C MTHFR gene, polymerase chain reaction (PCR), wild type
- 31 January 2016
- Published by Pesatuan Dokter Spesialis Mata Indonesia in Ophthalmologica Indonesiana
- Vol. 41 (2)
Open AccessIdentification of A1286C Methylenetetrahydrofolate Reductase Gene Polymorphism in Orbital Region Basal Cell Carcinoma Patients
Background: The development of basal cell carcinoma (BCC) shows variations among individuals. The risk factor for development of BCC related to environtmental factor especially exposure to ultraviolet radiation and individual factor. The one of internal risk factor contribute to basal cell carcinoma developmental is genetic instability include defects in folic acid synthesis or DNA synthesis. The critical enzim that participate in the process is regulated by Methylenetetrahydrofolate Reductase (MTHFR) gene. Method: This study was descriptive observational with case study involved 10 orbital region basal cell carcinoma. The diagnosis was based on histopathologic examination of the tumor. Genotype frequencies of A1286C polymorphism were studied by Polymerase Chain Reaction (PCR), amplification and restriction fragment length polymorphism analyses using MboII enzyme. Result: In the present study, from 10 subjects we found male was 7 people (70%) and female was 3 people (30%). Majority of subjects have history of having a job in the sunlight. The most commont of the BCC is nodular (80%). There is one subject with recurrent case. Analysis result of A1286C MTHFR gene show wild type in all cases. Conclusion: There’s no A1286C substitution methylenetetrahydrofolate reductase gene were identified. The whole subjects are wild type.Keywords: basal cell carcinoma, orbital region, folic acid, polymorphism, A1286C MTHFR gene, polymerase chain reaction (PCR), wild type